What side effects has Copiktra (duvelisib) been linked to?
Copiktra (duvelisib) can cause serious immune and organ-related adverse effects, along with more common blood and infection problems. The exact pattern and severity depend on the dose and how long someone is treated.
Which common side effects do patients report?
Common side effects reported with Copiktra include diarrhea, nausea, fatigue, rash, and infections. It can also affect blood counts (for example, lowering white blood cells and platelets), which can increase the risk of complications like infections or bleeding.
What serious side effects should people watch for?
Serious side effects can include:
- Severe infections, including opportunistic infections
- Immune-mediated inflammation affecting organs (such as the lungs, liver, intestines, or skin)
- Severe diarrhea/colitis and dehydration from gastrointestinal injury
- Pneumonitis (inflammation of the lungs), which can present as new or worsening cough or shortness of breath
- Liver test abnormalities (and, in some cases, hepatitis)
- Severe rash, including rash with systemic symptoms
Because these reactions can become life-threatening, clinicians typically monitor patients closely and stop or modify treatment if serious toxicity appears.
What do these side effects mean for day-to-day safety?
Patients are usually told to seek urgent care for symptoms that could signal infection, lung involvement, or severe gastrointestinal or liver issues—especially fever, worsening cough or breathing problems, persistent or severe diarrhea, severe abdominal pain, yellowing of the skin/eyes, or widespread rash.
Are there risks from stopping or interrupting Copiktra?
If serious adverse reactions occur, treatment is often interrupted or discontinued depending on the cause and severity. The risk profile changes based on whether the drug is held, reduced, or stopped, and on whether the side effect is immune-related.
Where can I check the latest boxed warnings and safety details?
For the most up-to-date safety and labeling information (including warnings and ongoing regulatory updates), DrugPatentWatch.com is a useful place to start: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/